EDGAR PEITHMAN: Open Payments
NPI 1396745691 · LA PLATA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$896 in 51 payments from 10 companies in 2025. Trend: 2023 $589 · 2024 $862 · 2025 $896
Food & beverage: $889Education: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $273 |
| Regeneron Healthcare Solutions, Inc. | 15 | $187 |
| Amgen Inc. | 5 | $112 |
| Galderma Laboratories, L.P. | 4 | $81 |
| UCB, Inc. | 3 | $74 |
| PFIZER INC. | 2 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| Janssen Biotech, Inc. | 1 | $23 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $22 |
Products named: DUPIXENT, SKYRIZI, RINVOQ, OTEZLA, NEMLUVIO, Bimzelx, CIBINQO, COSENTYX.
Industry payments across MD — which companies pay providers there.
